The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Charting the molecular network of the drug target Bcr-Abl
Open accessAbstract
The tyrosine kinase Bcr-Abl causes chronic myeloid leukemia and is the cognate target of tyrosine kinase inhibitors like imatinib. We have charted the protein–protein interaction network of Bcr-Abl by a 2-pronged approach. Using a monoclonal antibody we have first purified endogenous Bcr-Abl protein complexes from the CML K562 cell line and characterized the set of most tightly-associated interactors by MS. Nine interactors were subsequently subjected to tandem affinity purifications/MS analysis to obtain a molecular interaction network of some hundred cellular proteins. The resulting network revealed a high degree of interconnection of 7 “core” components around Bcr-Abl (Grb2, Shc1, Crk-I, c-Cbl, p85, Sts-1, and SHIP-2), and their links to different signaling pathways. Quantitative proteomics analysis showed that tyrosine kinase inhibitors lead to a disruption of this network. Certain components still appear to interact with Bcr-Abl in a phosphotyrosine-independent manner. We propose that Bcr-Abl and other drug targets, rather than being considered as single polypeptides, can be considered as complex protein assemblies that remodel upon drug action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Self-citation
Cited by
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Target profiling of small molecules by chemical proteomics
Rix, U., & Superti-Furga, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.216 · Cited by 575
Self-citationResponse and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Martinez Molina, D., & Nordlund, P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103715 · Cited by 306
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Moulick, K., Ahn, J. H., Zong, H., Rodina, A., Cerchietti, L., Gomes DaGama, E. M., Caldas-Lopes, E., Beebe, K., Perna, F., Hatzi, K., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.670 · Cited by 261
Metadata
- Authors
- Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Köcher, T., Mechtler, K., Bennett, K. L., & Superti-Furga, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-05-05
- Volume
- 106
- Issue
- 18
- Pages
- 7414-7419
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2067362444
- Cited by
- 170
- References
- 3
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Charting the molecular network of the drug target Bcr-Abl. https://app.cochat.ai/papers/10.1073/pnas.0900653106
- The paper
- Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Köcher, T., Mechtler, K., Bennett, K. L., & Superti-Furga, G. (2009). Charting the molecular network of the drug target Bcr-Abl. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0900653106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.